Recent Updates
Recently added Catalysts
IBRX Positive Sentiment

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ImmunityBio announced the treatment of the first patients in Europe with ANKTIVA® combined with BCG for BCG-unresponsive non-muscle invasive bladder cancer. This significant development took place in Germany and Austria, focusing on patients with carcinoma in situ and potentially papillary tumors. The combination aims to enhance treatment options for this challenging condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • First patients treated in Europe with ANKTIVA®
  • Combination therapy targets BCG-unresponsive NMIBC
  • Treatment administered in Germany and Austria

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+49%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakicept
Phase 1 · Metastatic Urothelial Carcinoma

Full Press Release Details

CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. The treatments were administered in Germany and Austria, marking an important step i

Frequently Asked Questions

What is ANKTIVA® used for?

It treats BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.

Where were the first patients treated?

Patients received treatment in Germany and Austria, marking the first European doses.

What does BCG stand for?

BCG stands for Bacillus Calmette-Guérin, used in combination with ANKTIVA®.

What type of cancer is targeted?

The therapy targets non-muscle invasive bladder cancer with carcinoma in situ.

ShareAdd on Google
Tags: IBRX ImmunityBio ANKTIVA BCG bladder cancer non-muscle invasive
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$357M liquidity · $22M/mo burn
~13 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakiceptPhase 1
Metastatic Urothelial Carcinoma →

Catalyst track record

+49%
best trade around IBRX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for IBRX.

See every catalyst's timing & PoA →